GLAND PHARMA LIMITED

August 09, 2026

BSE Limited
Corporate Relationship Department
Phiroze Jeejeebhoy Towers
25th floor, Dalal Street
Mumbai - 400 001
Scrip Code: 543245

National Stock Exchange of India Limited
Listing Department
Exchange Plaza, 5th floor
Plot no. C-1, Block G, Bandra Kurla Complex
Bandra (East), Mumbai - 400 051
Symbol: GLAND (ISIN: INE068V01023)

Dear Sir/Madam,

Sub: Press Release - Gland Pharma Announces Strategic CDMO Partnership with A Global Pharmaceutical Company

Pursuant to Regulation 30 read with Part A of Schedule III of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015; please find attached Press Release titled "***Gland Pharma announces Strategic CDMO Partnership with A Global Pharmaceutical Company***".

Further, the details required under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026, are enclosed as **Annexure A.**

This is for your information and records.

Yours truly,

For Gland Pharma Limited

Pallerlamudi Sampath Kumar

Digitally signed by Pallerlamudi Sampath Kumar
DN: cn=Pallerlamudi Sampath Kumar, c=IN, o=Personal, email=sampath@glandpharma.com
Date: 2026.08.09 09:22:53 +05'30'

Sampath Kumar Pallerlamudi
Company Secretary & Compliance Officer

Encl: Press Release & Annexure A

Press Release

Gland Pharma Announces Strategic CDMO Partnership with a Global Pharmaceutical Company

Hyderabad, August 09, 2026: Gland Pharma Limited (BSE: 543245, NSE: GLAND) today announced the execution of a strategic Manufacturing and Supply Agreement (MSA) with one of the leading global pharmaceutical companies for the Technology Transfer, Manufacturing and Supply of a portfolio of sterile injectable products for global markets.

The partnership establishes Gland Pharma as an integrated end-to-end partner supporting multiple products across various stages of the product lifecycle, including both commercially marketed products and pipeline products under development. The collaboration follows a full-service CDMO model encompassing technology transfer, process development, scale-up, validation, commercial manufacturing, and long-term supply of sterile injectable products.

The portfolio comprises a diversified basket of oncology and non-oncology products in Vial, Lyo, Ampoules and pre-filled syringe (PFS) presentations, covering both complex and conventional injectable formulations. Under the agreement, Gland Pharma will leverage its integrated capabilities across development, technology transfer, manufacturing, quality and regulatory support to provide a comprehensive "one-stop" solution to its partner.

The agreement is expected to provide strong long-term business visibility, with revenue generation anticipated from calendar year 2029. The current agreement covers 55 SKUs to be manufactured across three sites, with scope of adding more products soon. Once all products are commercialized, the annualized revenue potential is expected to be approximately USD 90–100 million. Technology transfer activities are planned for completion within two years, with revenues expected to commence from calendar year 2029.

The partnership represents an important milestone in Gland Pharma's growth journey and further strengthens its position as a trusted global CDMO partner for pharmaceutical companies seeking a full-service model including integrated development, technology transfer and manufacturing solutions for sterile injectable products.

Mr. Srinivas Sadu, Executive Chairman, Gland Pharma Limited, said:

“We are pleased to enter into this strategic collaboration. The partnership highlights the confidence global pharmaceutical companies place in Gland Pharma's development, technology transfer, manufacturing, and supply capabilities. The agreement provides meaningful long-term revenue visibility, supports expansion of our CDMO business, and creates a strong foundation for future growth. We remain committed to investing in the capabilities and capacity required to support our partner's evolving needs and ensure reliable supply to patients worldwide.”

About Gland Pharma Limited (BSE: 543245, NSE: GLAND)

Gland Pharma was established in 1978 in Hyderabad and has grown over the years from a contract manufacturer of small-volume liquid parenteral products to become one of the largest injectable-focused companies, with a global footprint across 60 countries, including the United States, Europe, Canada, Australia, India, and other markets. It operates primarily under CDMO & business-to-business (B2B) model and has an excellent track record in developing, manufacturing, and marketing sterile injectables. It has a wide range of injectables, including vials, ampoules, pre-filled syringes, lyophilized vials, dry powders, infusions, oncology, and ophthalmic solutions.

It also enjoys the distinction of having pioneered Heparin technology in India. For more information, log on to: www.glandpharma.com.

For investor queries, please mail us at investors@glandpharma.com

This press release may include statements of future expectations and other forward-looking statements based on management's current expectations and beliefs. Actual results may vary materially from those expressed or implied by the statements herein due to economic, business, competitive, technological, and/or regulatory factors changes. Gland Pharma Limited, its directors, and any of the affiliates or employees are under no obligation to, and expressly assume, any obligation to update any particular forward-looking statement contained in this release

Annexure A

Particulars	Remarks
Type of arrangement	CDMO Partnership / Agreement
Name of the entity with whom agreement is signed	Global Pharmaceutical Company [Name cannot be disclosed due to confidentiality obligations]
Area of agreement	A Strategic Manufacturing and Supply Agreement (MSA) for the Technology Transfer, Manufacturing and Supply of a portfolio of sterile injectable products for global markets. The product portfolio comprises a diversified basket of oncology and non-oncology products in vial, Lyo, Ampoules and pre-filled syringe (PFS) presentations, covering both complex and conventional injectable formulations. Under the agreement, Gland Pharma will leverage its integrated capabilities across development, technology transfer, manufacturing, quality and regulatory support to provide a comprehensive "one-stop" solution to its partner.
Domestic / International	International
Share exchange ratio / JV ratio	Not Applicable
Scope of business operation of agreement	Full-service CDMO model encompassing technology transfer, process development, scale-up, validation, commercial manufacturing, and long-term supply of sterile injectable products.
Details of consideration paid / received in agreement	The agreement is expected to provide strong long-term business visibility, with revenue generation anticipated from calendar year 2029. The current agreement covers 55 SKUs to be manufactured across three sites, with scope of adding more products soon. Once all products are commercialized, the annualized revenue potential is expected to be approximately USD 90–100 million.
Significant terms and conditions of agreement in brief	Full-service CDMO model encompassing technology transfer, process development, scale-up, validation, commercial manufacturing, and long-term supply of sterile injectable products.
Whether the acquisition would fall within related party transactions	Not Applicable

Whether the promoter/ promoter group/ group companies have any interest in the entity being acquired?	Not Applicable
If yes, nature of interest and details thereof	Not Applicable
Whether the same is done at "arm's length"	Not Applicable
Size of the entity	Cannot be disclosed due to confidentiality obligations
Rationale and benefit expected	The agreement is expected to provide strong long-term business visibility, with revenue generation anticipated from calendar year 2029. The current agreement covers 55 SKUs to be manufactured across three sites, with scope of adding more products soon. Once all products are commercialized, the annualized revenue potential is expected to be approximately USD 90–100 million.